To add a bio or update investment portfolio click update information.
LifeArc Ventures
Investment Portfolio
RQ Bio
25 Jun 2026
RQ Bio raises a £86m Series A led by Frazier Life Sciences to develop long-acting antibody protection against seasonal influenza
RQ Bio is a UK-based biotechnology company developing long-acting monoclonal antibodies against seasonal influenza. Its lead programme, RQB01, is designed to deliver potent, broad-strain protection against influenza through a dual mechanism of action, targeting patients whose immune systems cannot rely on vaccination alone.
Cytospire Therapeutics
5 May 2026
Cytospire Therapeutics secures £61m Series A led by 4BIO Capital for cancer therapies that activate the body’s immune cells
Cytospire Therapeutics develops multispecific immune cell engager antibodies designed to enhance and direct the activity of the body’s immune system. Its platform targets gamma delta T cells to generate anti tumour immune responses for patients with cancer and other diseases.
LifeArc Ventures
More venture news
- 12 Aug 2026
MindgardMindgard secures £22m Series A led by Album VC to test and defend AI systems against adversarial attack
Series ACybersecurity - 12 Aug 2026
CytixCytix raises a £5m Series A round led by Northern Gritstone to manage the security risk of AI-driven software change
Series ACybersecurity - 29 Jul 2026
LemonEdgeLemonEdge announced £16m Series A round led by Blackstone Innovations Investments for a fund accounting platform built for private markets
Series AFintech
